Avalo Therapeutics, Inc. — Form 4
Filed August 19, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 54/100
What the filing says
Chief Financial Officer Sullivan Christopher Ryan (AVTX) sold 145K shares (~$1.5M) on the open market (60% of holdings). Large sale — ~60% of holdings.
Why this rating
Large sale — ~60% of holdings.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.